Epclusa Access Issues: What Providers and Prescribers Need to Know in 2026

Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) remains one of the most broadly indicated and highly effective direct-acting antiviral (DAA) regimens available for chronic hepatitis C. With sustained virologic response (SVR12) rates of 95–99% across genotypes 1–6 and a straightforward 12-week once-daily regimen, it is a first-line option in AASLD-IDSA HCV guidance for the majority of HCV-infected patients.

Despite strong clinical performance, providers in 2026 continue to encounter significant access barriers when prescribing Epclusa. This guide covers the key obstacles, clinical considerations, and practical strategies to help your patients get the treatment they need.

Current Availability Status

Epclusa is not listed on the FDA Drug Shortage Database or the ASHP shortage list as of 2026. Gilead Sciences has not reported manufacturing disruptions. The authorized generic (sofosbuvir/velpatasvir by Asegua Therapeutics, a Gilead affiliate) remains available. Access barriers are systemic — driven by cost, insurance requirements, and pharmacy stocking patterns — rather than supply chain disruption.

Prior Authorization: What Payers Typically Require

Nearly all payers — commercial, Medicare Part D, and state Medicaid programs — require prior authorization for Epclusa. While specific requirements vary by plan, typical documentation requests include:

• Confirmed diagnosis of chronic HCV with positive HCV RNA (quantitative PCR)
• HCV genotype (genotype 1–6 for Epclusa; all are covered)
• Liver fibrosis stage (FIB-4, FibroScan, or liver biopsy results)
• Prior treatment history (treatment-naïve vs. treatment-experienced)
• HBsAg and anti-HBc testing results (required per boxed warning)
• Absence of absolute contraindications (e.g., amiodarone use)

Tip: Submit PA requests with comprehensive documentation from the outset to minimize back-and-forth with payers. Use the ICD-10 code B18.2 for chronic hepatitis C without mention of hepatic coma (or B18.1 with coma), and specify Child-Pugh class when relevant.

Step Therapy: When Payers Require Mavyret First

Some commercial payers implement step therapy, requiring patients to try Mavyret (glecaprevir/pibrentasvir) before approving Epclusa coverage. From a clinical standpoint, this is often acceptable for treatment-naïve patients without cirrhosis or with compensated cirrhosis who have any genotype 1–6.

However, step therapy for Epclusa is clinically inappropriate in certain patient populations. Document and argue for step therapy exemption in the following situations:

• Decompensated cirrhosis (Child-Pugh B or C): Mavyret is contraindicated. Epclusa + ribavirin is the standard of care per AASLD guidance.
• Prior NS3/4A protease inhibitor exposure: Mavyret contains an NS3/4A inhibitor. In patients who have failed a previous PI-containing regimen, Epclusa (or Vosevi) is preferred.
• Complex drug interactions specific to glecaprevir: Some patients on drugs that interact significantly with Mavyret but not with Epclusa may be better candidates for Epclusa.

The Boxed Warning: HBV Reactivation

Epclusa carries a boxed warning for risk of hepatitis B virus (HBV) reactivation in HCV/HBV coinfected patients. Before initiating therapy, screen all patients with HBsAg and anti-HBc. Patients who are HBsAg positive should be started on HBV antiviral therapy before or concurrent with Epclusa. Patients with evidence of resolved HBV (HBsAg negative, anti-HBc positive) should be monitored closely during and after HCV treatment.

Key Drug Interactions for Clinical Practice

The most clinically important interactions to review before prescribing Epclusa include:

• Amiodarone (Cordarone, Pacerone): Contraindicated. Risk of serious symptomatic bradycardia, including cases requiring pacemaker insertion or resulting in death.
• Proton pump inhibitors: Not recommended. PPIs reduce velpatasvir absorption significantly. If unavoidable, administer Epclusa with food and use the lowest PPI dose 4 hours before Epclusa.
• Strong P-gp/CYP inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort, efavirenz): Decrease sofosbuvir and velpatasvir levels. Avoid concurrent use.
• Topotecan: Avoid. Velpatasvir increases topotecan exposure significantly.
• Tenofovir DF: Monitor for tenofovir-associated adverse effects (renal toxicity, bone toxicity) when coadministering.

Financial and Access Resources for Your Patients

When patients can't access Epclusa due to financial or insurance barriers, the following programs are available:

• Gilead Support Path: 1-855-769-7284 | MySupportPath.com — PA support, specialty pharmacy routing, co-pay assistance, and patient assistance for uninsured/underinsured patients
• Epclusa Co-pay Card: Commercially insured patients may pay as little as $5/month; up to 25% of catalog price for 3 bottles over 6 months
• Medicaid: Covered in all 50 states; most programs have $0–$5 copays; prior auth criteria vary by state
• ADAP (AIDS Drug Assistance Program): For HCV/HIV coinfected patients without adequate insurance coverage
• Medfinder for Providers:medfinder.com/providers — helps your patients locate which nearby pharmacies have Epclusa available
• Medfinder for Providers: medfinder.com/providers — helps your patients locate which nearby pharmacies have Epclusa available

Monitoring During Epclusa Therapy

For most patients, HCV RNA testing at end of treatment and SVR12 (12 weeks post-treatment) is sufficient. For patients with decompensated cirrhosis on Epclusa + ribavirin, monitor liver function (LFTs, direct bilirubin) throughout treatment, as clinically indicated. Monitor for HBV reactivation in coinfected patients.

For a more detailed guide on helping your patients locate Epclusa, see our provider's guide to finding Epclusa in stock.